Published in:
24-02-2024 | Esophageal Cancer | ASO Author Reflections
ASO Author Reflections: Clinical Impact of Conversion Surgery After Induction Therapy for Esophageal Cancer with Synchronous Distant Metastasis: A Multi-institutional, Retrospective Study
Authors:
Keijiro Sugimura, MD, PhD, Koji Tanaka, MD, PhD, Takahito Sugase, MD, PhD, Kota Momose, MD, PhD, Takashi Kanemura, MD, PhD, Kotaro Yamashita, MD, PhD, Tomoki Makino, MD, PhD, Osamu Shiraishi, MD, PhD, Masaaki Motoori, MD, PhD, Makoto Yamasaki, MD, PhD, Hiroshi Miyata, MD, PhD, Kazumasa Fujitani, MD, PhD, Takushi Yasuda, MD, PhD, Masahiko Yano, MD, PhD, Hidetoshi Eguchi, MD, PhD, Yuichiro Doki, MD, PhD
Published in:
Annals of Surgical Oncology
|
Issue 5/2024
Login to get access
Excerpt
The eighth edition of the Union for International Cancer Control (UICC) staging system categorizes esophageal cancer with synchronous distant metastasis as Stage 4. To date, chemotherapy remains the standard treatment for Stage 4b esophageal cancer. For more than two decades, the combination of two drugs, cisplatin and 5-fluorouracil (5-FU), has been the standard chemotherapy for synchronous distant metastatic esophageal cancer. However, the treatment results are dismal; median survival has been assumed to be 7.6 to 10.2 months. To date, conversion surgery has been attempted for gastrointestinal cancer with synchronous distant metastasis if there is a response to chemotherapy.
1 However, conversion surgery for esophageal cancer with synchronous distant metastasis is not yet an established treatment. …
